Aadi Bioscience to Participate in Upcoming Investor Events

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Aadi Bioscience to Participate in Upcoming Investor Events

PR Newswire

LOS ANGELES, May 23, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced today participation at the following investor events:

  • TD Cowen's 4th Annual Oncology Innovation Summit:  Insights for ASCO & EHA - The virtual event, taking place May 30 - 31, 2023, incorporates fireside chats hosted by members of TD Cowen research team that focus on various aspects of health care. Scott Giacobello, Interim CEO and President and CFO of Aadi, will participate in a fireside chat on Tuesday, May 30, 2023, at 11:30 am ET
  • Jefferies Global Healthcare Conference – The conference will take place June 7-9, 2023, in New York City.  Mr. Giacobello will participate in a fireside chat on Thursday, June 8, 2023, at 11:00 am ET.  Company management will also participate in one-on-one meetings with investors during the conference. 

The fireside chats will be webcast live on the IR pages of the Aadi Biosciences website and will be available for replay for approximately 30 days following each investor event.

About Aadi Bioscience, Inc.
Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Aadi received FDA approval in November 2021, and in February 2022 commenced commercialization of FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi is conducting the PRECISION 1 trial, a Phase 2 tumor-agnostic registration-directed study in patients with mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on Aadi's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:
Marcy Graham
[email protected] 

(PRNewsfoto/Aadi Bioscience)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-participate-in-upcoming-investor-events-301832033.html

SOURCE Aadi Bioscience

Copyright CNW Group 2023

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).